The FDA has approved semaglutide (Ozempic, Novo Nordisk) for the reduction of major adverse cardiovascular (CV) events in patients with type 2 diabetes and established CV disease.
A new study examined diabetes as an independent predictor of heart failure.
The approvals were granted to generic apixaban applications from Micro Labs Limited and Mylan Pharmaceuticals Inc.
Pharmacist-led initiatives, such as medication therapy management, for chronic diseases can significantly improve patient outcomes.
Statin regimens may need tweaking to deliver optimal results.
Results presented at the 2019 NCPA Annual Convention
Two different versions of tafamadis get the FDA’s nod to treat a rare heart disease.